Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

ClinicalTrials.gov ID: NCT01111552

Public ClinicalTrials.gov record NCT01111552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an incomplete response to a prospective trial of Escitalopram, and report a treatment history for the current MDD episode of an inadequate response to at least one and no more than three adequate trials of an approved antidepressant other than Escitalopram. An inadequate response is defined as less than a 50% reduction in depressive symptom severity as assessed by the participant's self-report on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and evaluated by the investigator as part of the participant's medical and psychiatric history. An adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for combination treatments) at an approved dose as specified in the ATRQ.

Study identification

NCT ID
NCT01111552
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Enrollment
237 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 29, 2010 (Actual)
Primary completion
Sep 27, 2011 (Actual)
Completion
Sep 27, 2011 (Actual)
Last update posted
Oct 26, 2021

2010 – 2011

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Not listed Birmingham Alabama 35216 —
Not listed Little Rock Arkansas 72223 —
Not listed Carson California 90746 —
Not listed Garden Grove California 95231 —
Not listed Imperial California 92251 —
Not listed Mission Viejo California 92691 —
Not listed Redlands California 92374 —
Not listed San Diego California 92128 —
Not listed Atlanta Georgia 30308 —
Not listed Atlanta Georgia 30328 —
Not listed Hoffman Estates Illinois 60169 —
Not listed Terre Haute Indiana 47802 —
Not listed Overland Park Kansas 66211 —
Not listed Prairie Village Kansas 66206 —
Not listed Wichita Kansas 67207 —
Not listed Baltimore Maryland 21204 —
Not listed New York New York 10021 —
Not listed Toledo Ohio 43623 —
Not listed Bartlett Tennessee 38134 —
Not listed Wichita Falls Texas 76309 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01111552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 26, 2021 · Synced Oct 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01111552 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →